Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424213 · ClinicalTrials.gov registry record
Race-related Alternative Splicing: Novel Targets in Prostate Cancer
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 169
- Enrollment target
NCT03424213: Completed study, sponsored by Duke University.
NCT03424213 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03424213 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
Study Summary
Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA men. Coded archival radical prostatectomy tissue specimens and annotated clinical data, questionnaire data, and ancestral genotyping data will be obtained from the racially diverse and federally funded North Carolina-Louisiana PCa Project (NC-LA PCaP). We will use 33 tissue specimens from each of the following 6 groups (n=198 total): white low aggressive, white intermediate aggressive, white high aggressive, AA low aggressive, AA intermediate aggressive and AA high aggressive. The aforementioned tissues will first be screened for tumor content and Gleason grade by a genitourinary pathologist. To identify race-related splice variants, RNA will be isolated for targeted sequencing of prioritized race-related alternatively spliced genes using the NimbleGen SeqCap Target Enrichment, SeqCap RNA System to capture regions of interest and the Illumina HiSeq sequencing platform to sequence these regions at a depth and coverage sufficient to accurately call alternative splicing events.
Interventions
- OTHER No interventions - retrospective data collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2021-07-14 |
What the finished NCT03424213 record still lists
NCT03424213 is an observational study that tracks outcomes without assigning an intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No interventions - retrospective data collection is the first listed.
NCT03424213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03424213 about?
NCT03424213 is a clinical study titled "Race-related Alternative Splicing: Novel Targets in Prostate Cancer". Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA men. Coded archival radical prostatectomy tissue specimens and annotated clinical data, questionnai...
What is the current status of trial NCT03424213?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2018-01-30. Estimated completion is 2021-07-14.
What interventions are being tested in trial NCT03424213?
The interventions under investigation include: No interventions - retrospective data collection (OTHER).
Who is sponsoring clinical trial NCT03424213?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI